GLP-1 reduces adverse cardiac events before weight loss: 3 notes
Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity. Here are three notes from the secondary analysis: The “Semaglutide and Cardiovascular Outcomes … Read more